Charalampopoulou S, Chapiro E, Nadeu F, Zenz T, Bea S, Martinez-Farran A
Blood Adv. 2024; 8(24):6297-6307.
PMID: 39471431
PMC: 11700275.
DOI: 10.1182/bloodadvances.2024013327.
Blombery P, de Jong D, Ferry J, Hsi E, Ondrejka S, Seymour J
Histopathology. 2024; 86(1):69-78.
PMID: 39403047
PMC: 11648355.
DOI: 10.1111/his.15323.
Hibbs S, Smith M, Swinglehurst D
Hemasphere. 2024; 8(2):e35.
PMID: 38436554
PMC: 10878189.
DOI: 10.1002/hem3.35.
Troussard X, Maitre E
J Cell Mol Med. 2023; 28(3):e18060.
PMID: 38095234
PMC: 10844692.
DOI: 10.1111/jcmm.18060.
Menakuru S, Roepke J, Siddiqui S
J Hematol. 2023; 12(2):82-86.
PMID: 37187496
PMC: 10181324.
DOI: 10.14740/jh1096.
De novo chronic lymphocytic leukemia/prolymphocytic leukemia or B-cell prolymphocytic leukemia? The importance of integrating clinico-morphological and immunophenotypic findings in distinguishing chronic lymphoproliferative diseases with circulating....
Chowdhury Z, Khonglah Y, Sarma S, Kalita P
Autops Case Rep. 2021; 11:e2020196.
PMID: 34277479
PMC: 8101659.
DOI: 10.4322/acr.2020.196.
Shikonin Derivatives from Decrease Expression of Phosphorylated STAT3 in Leukemia Cells and Exert Antitumor Activity.
Todorovic Z, Milovanovic J, Arsenijevic D, Vukovic N, Vukic M, Arsenijevic A
Nutrients. 2021; 13(4).
PMID: 33807148
PMC: 8065735.
DOI: 10.3390/nu13041147.
B-cell Prolymphocytic Leukemia: Case Report and Challenges on a Diagnostic and Therapeutic Forefront.
Bindra B, Kaur H, Portillo S, Emiloju O, Garcia de de Jesus K
Cureus. 2019; 11(9):e5629.
PMID: 31700732
PMC: 6822919.
DOI: 10.7759/cureus.5629.
Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A, Wanquet A, Maitre E, Cornet E, Troussard X, Aurran-Schleinitz T
Curr Oncol Rep. 2017; 19(4):29.
PMID: 28324286
DOI: 10.1007/s11912-017-0581-x.
Immunoglobulin gene translocations in chronic lymphocytic leukemia: A report of 35 patients and review of the literature.
De Braekeleer M, Tous C, Gueganic N, Le Bris M, Basinko A, Morel F
Mol Clin Oncol. 2016; 4(5):682-694.
PMID: 27123263
PMC: 4840758.
DOI: 10.3892/mco.2016.793.
Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.
Brogden R, Sorkin E
Drugs. 1993; 46(4):652-77.
PMID: 7506651
DOI: 10.2165/00003495-199346040-00006.
Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes).
Tolksdorf G, STEIN H, Lennert K
Br J Cancer. 1980; 41(2):168-82.
PMID: 7370158
PMC: 2010202.
DOI: 10.1038/bjc.1980.27.
Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces.
Hamblin T, Gordon J, Stevenson F, Stevenson G
Br J Cancer. 1980; 42(4):495-502.
PMID: 7192154
PMC: 2010447.
DOI: 10.1038/bjc.1980.271.
BCL1, a murine model of prolymphocytic leukemia. I. Effect of splenectomy on growth kinetics and organ distribution.
Muirhead M, Isakson P, Krolick K, UHR J, Vitetta E
Am J Pathol. 1981; 105(3):295-305.
PMID: 7032308
PMC: 1903899.
Some aspects of immunological and cytochemical markers in leukemia.
Huhn D
Cancer Chemother Pharmacol. 1980; 4(4):237-42.
PMID: 7002343
DOI: 10.1007/BF00255267.
BCL1, a murine model of prolymphocytic leukemia. II. Morphology and ultrastructure.
Muirhead M, Holbert Jr J, UHR J, Vitetta E
Am J Pathol. 1981; 105(3):306-15.
PMID: 6976124
PMC: 1903889.
DNA content of leukaemic cells in non-Hodgkin's lymphomas of low-grade malignancy. Flow-cytometric and morphological investigations with special regard to hyperploid cells.
Dullmann J, Wulfhekel U, LINDEN W, Beck H, Hausmann K
Blut. 1980; 41(6):427-35.
PMID: 6934838
DOI: 10.1007/BF01007767.
Some data on the proliferative activity of prolymphocytic leukemia.
Donhuijsen K, Richter H
Klin Wochenschr. 1980; 58(5):259-60.
PMID: 6931266
DOI: 10.1007/BF01476972.
B-lineage prolymphocytic leukemia as a distinct clinicopathologic entity.
Katayama I, Aiba M, Pechet L, Sullivan J, Roberts P, Humphreys R
Am J Pathol. 1980; 99(2):399-412.
PMID: 6929655
PMC: 1903496.
Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibody.
Gordon J, Hamblin T, Stevenson F, Stevenson G
Br J Cancer. 1984; 49(5):547-57.
PMID: 6722005
PMC: 1976721.
DOI: 10.1038/bjc.1984.88.
